Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis

BACKGROUND: Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggesting increased morta...

Descripción completa

Detalles Bibliográficos
Autores principales: Longardner, Katherine, Wright, Brenton A., Alakkas, Aljoharah, You, Hyeri, Xu, Ronghui, Liu, Lin, Nahab, Fatta B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882782/
https://www.ncbi.nlm.nih.gov/pubmed/36706079
http://dx.doi.org/10.1371/journal.pone.0278262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882782/
https://www.ncbi.nlm.nih.gov/pubmed/36706079
http://dx.doi.org/10.1371/journal.pone.0278262

Ejemplares similares